Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function

Sci Rep. 2015 May 5:5:10034. doi: 10.1038/srep10034.

Abstract

A total of 142 premenopausal women with symptomatic adenomyosis underwent ultrasound (US)-guided percutaneous microwave ablation (PMWA) at the Chinese PLA General Hospital. This study aimed to evaluate changes in serum pituitary, gonadal hormone and cancer antigen 125 (CA125) levels after US-guided PMWA. Therefore, estradiol (E2), follicle-stimulating hormone (FSH), prolactin (PRL) and CA125 levels were evaluated before ablation and at 3, 6, 9 and 12 months after ablation. No significant differences were observed in the E2 and FSH levels pre-ablation and during follow-up (E2: p=0.933, p=0.987, p=0.106, p=0.936; FSH: p=0.552, p=0.295, p=0.414, p=0.760). The mean absolute values of serum CA125 and PRL were significantly decreased at 3, 6, 9 and 12 months after ablation (CA125: p<0.001, p<0.001, p<0.001, p=0.003; PRL: p<0.001, p<0.001, p<0.001, p<0.001). A significant correlation between changes in CA125 levels and uterine volume was found (p<0.001). No evidence of a decline in ovarian function was observed after US-guided PMWA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenomyosis / blood
  • Adenomyosis / physiopathology*
  • Adenomyosis / therapy*
  • Adult
  • CA-125 Antigen / blood
  • Female
  • Humans
  • Membrane Proteins / blood
  • Microwaves*
  • Middle Aged
  • Ovary / physiopathology*
  • Treatment Outcome
  • Ultrasonics*

Substances

  • CA-125 Antigen
  • MUC16 protein, human
  • Membrane Proteins